[go: up one dir, main page]

YU90301A - Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane - Google Patents

Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane

Info

Publication number
YU90301A
YU90301A YU90301A YUP90301A YU90301A YU 90301 A YU90301 A YU 90301A YU 90301 A YU90301 A YU 90301A YU P90301 A YUP90301 A YU P90301A YU 90301 A YU90301 A YU 90301A
Authority
YU
Yugoslavia
Prior art keywords
conjugates
transport
molecules
production
biological membranes
Prior art date
Application number
YU90301A
Other languages
English (en)
Inventor
Eugen Uhlmann
Beate Greiner
Eberhard Unger
Gislinde Gothe
Marc Schwerdel
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Priority to MEP-564/08A priority Critical patent/MEP56408A/xx
Publication of YU90301A publication Critical patent/YU90301A/sh
Publication of RS51447B publication Critical patent/RS51447B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Predmet ovog pronalaska su konjugati, postupci za njihovu proizvodnju i primena tih konjugata za transport niskomolekularnih jedinjenja i makromolekula kroz biološke membrane, posebno za transport molekula u ćelije. Predmet ovog pronalaska su i lekovi i sredstva dijagnostike, kao i test-kompleti, u kojima se ovi konjugati nalaze, odn. primenjuju.
YUP-903/01A 1999-07-28 2000-07-20 Konjugati i postupci za njihovu proizvodnju, i njihova upotreba za transport molekula kroz biološke membrane RS51447B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-564/08A MEP56408A (en) 1999-07-28 2000-07-20 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19935302A DE19935302A1 (de) 1999-07-28 1999-07-28 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen

Publications (2)

Publication Number Publication Date
YU90301A true YU90301A (sh) 2004-05-12
RS51447B RS51447B (sr) 2011-04-30

Family

ID=7916258

Country Status (32)

Country Link
US (1) US8420396B2 (sh)
EP (1) EP1204430B1 (sh)
JP (1) JP4791665B2 (sh)
KR (1) KR100721696B1 (sh)
CN (1) CN1227035C (sh)
AR (1) AR029385A1 (sh)
AT (1) ATE447413T1 (sh)
AU (1) AU776114B2 (sh)
BR (1) BR0012757A (sh)
CA (1) CA2377977C (sh)
CY (1) CY1109744T1 (sh)
CZ (1) CZ2002300A3 (sh)
DE (2) DE19935302A1 (sh)
DK (1) DK1204430T3 (sh)
EE (1) EE05303B1 (sh)
ES (1) ES2335741T3 (sh)
HR (1) HRP20020074B1 (sh)
HU (1) HUP0201995A3 (sh)
IL (2) IL147527A0 (sh)
ME (1) MEP56408A (sh)
MX (1) MXPA01013114A (sh)
NO (1) NO334155B1 (sh)
NZ (1) NZ516838A (sh)
PL (1) PL202881B1 (sh)
PT (1) PT1204430E (sh)
RS (2) RS20100249A (sh)
RU (1) RU2275936C2 (sh)
SI (1) SI1204430T1 (sh)
SK (1) SK287654B6 (sh)
TR (4) TR200706709T2 (sh)
WO (1) WO2001008707A2 (sh)
ZA (1) ZA200200657B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
ATE520784T1 (de) * 2003-09-11 2011-09-15 Universitaetsklinikum Schleswig Holstein Campus Luebeck Den transmembrantransport von nukleinsäuren fördernde nukleotidsequenzen
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1886681A3 (en) * 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-hydroxyphenyl)-3H-1,2-dithiol-3-thione valproate ester
KR100690199B1 (ko) * 2006-04-20 2007-03-12 이화여자대학교 산학협력단 구리 이온 선택성을 갖는 플루오레세인 유도체, 이의제조방법 및 이를 이용한 생체 내 구리 이온 검출방법
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
KR20130108655A (ko) 2010-12-29 2013-10-04 에프. 호프만-라 로슈 아게 핵산의 세포내 전달을 위한 소분자 접합체
MX381946B (es) 2014-05-23 2025-03-13 Genzyme Corp Restos oligonucleotidicos multiples sobre soporte peptidico.
EP3493855A4 (en) * 2016-08-02 2020-04-01 ISI Life Sciences, Inc. COMPOSITIONS AND METHOD FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
US10539567B2 (en) * 2017-05-15 2020-01-21 Indicator Systems International, Inc. Biopsy methods and devices
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
KR20230096856A (ko) 2021-12-22 2023-06-30 한국과학기술연구원 신규 펩타이드-올리고뉴클레오티드 접합체 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801070D0 (sv) * 1988-03-23 1988-03-23 Pharmacia Ab Method for immobilizing a dna sequence on a solid support
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
WO1995006659A1 (en) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
RU2094059C1 (ru) * 1993-08-30 1997-10-27 Московский государственный университет, химический факультет Способ транспорта нейротропных препаратов в мозг
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
RU2127606C1 (ru) * 1994-12-23 1999-03-20 Санкт-Петербургский государственный университет Способ получения растворимых ковалентных конъюгатов
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US5698411A (en) * 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
DE19824535A1 (de) * 1998-06-03 1999-12-09 Roche Diagnostics Gmbh Neue Rhodamin-Derivate und deren Verwendung
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6080580A (en) * 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US7005123B1 (en) 1999-06-17 2006-02-28 Universiteit Gent Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application

Also Published As

Publication number Publication date
NO20020367L (no) 2002-03-26
RS51447B (sr) 2011-04-30
NO20020367D0 (no) 2002-01-23
PL353069A1 (en) 2003-10-06
WO2001008707A3 (de) 2001-11-08
KR100721696B1 (ko) 2007-05-28
AR029385A1 (es) 2003-06-25
IL147527A (en) 2006-08-01
DK1204430T3 (da) 2010-03-29
ES2335741T3 (es) 2010-04-05
SK1172002A3 (en) 2002-08-06
DE50015781D1 (de) 2009-12-17
RS20100249A (sr) 2011-02-28
DE19935302A1 (de) 2001-02-08
CN1360507A (zh) 2002-07-24
AU6825200A (en) 2001-02-19
SI1204430T1 (sl) 2010-03-31
US8420396B2 (en) 2013-04-16
TR200200222T2 (tr) 2002-07-22
PL202881B1 (pl) 2009-07-31
CA2377977A1 (en) 2001-02-08
HRP20020074B1 (en) 2011-01-31
CN1227035C (zh) 2005-11-16
EP1204430A2 (de) 2002-05-15
ZA200200657B (en) 2003-09-23
EP1204430B1 (de) 2009-11-04
HRP20020074A2 (en) 2005-10-31
JP2003505517A (ja) 2003-02-12
HUP0201995A2 (en) 2002-10-28
ATE447413T1 (de) 2009-11-15
CZ2002300A3 (cs) 2002-05-15
HUP0201995A3 (en) 2005-02-28
EE200200035A (et) 2003-04-15
KR20020031392A (ko) 2002-05-01
SK287654B6 (sk) 2011-05-06
US20080071069A1 (en) 2008-03-20
CA2377977C (en) 2011-09-20
IL147527A0 (en) 2002-08-14
TR201109493T2 (tr) 2012-03-21
RU2275936C2 (ru) 2006-05-10
NO334155B1 (no) 2013-12-23
HK1047042A1 (en) 2003-02-07
MEP56408A (en) 2011-05-10
EE05303B1 (et) 2010-06-15
MXPA01013114A (es) 2002-06-04
BR0012757A (pt) 2002-04-02
CY1109744T1 (el) 2014-09-10
AU776114B2 (en) 2004-08-26
NZ516838A (en) 2004-07-30
PT1204430E (pt) 2010-01-26
JP4791665B2 (ja) 2011-10-12
TR200706709T2 (tr) 2008-02-21
WO2001008707A2 (de) 2001-02-08
TR201109491T2 (tr) 2012-02-21

Similar Documents

Publication Publication Date Title
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EP3190180A3 (en) A method for identifying, expanding, and removing adult stem cells and cancer stem cells
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
ECSP066461A (es) Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados
PT2327763T (pt) Geração de células t específicas de antigénios
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2006076691A8 (en) Irta-2 antibodies and their uses
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
BRPI0409187A (pt) composição farmacêutica contendo um imunossupressor para uso no tratamento de doenças de pele
ATE469936T1 (de) Modifiziertes polymer und modifizierte polymermembran
DE50015987D1 (de) Konjugat zur vermittlung eines zell-, kompartimenttanzen
ATE361469T1 (de) Methoden zur introduktion heterologer zellen in fische
WO2001042283A3 (en) Sex-chromosome-specific proteins, species specific and sperm specific proteins and methods for their identification and isolation
IL161341A (en) Sensitivity controls for blood serology prepared from modified cells
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE60138531D1 (de) Fluoreszierende im membran interkalierende proben und verfahren zu deren verwendung
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln